Allon granted important U.S. patent for preclinical compound AL-408
Allon Therapeutics Inc. announced that it has been granted an important United States patent covering the composition of matter for the D-isomer of NAP (davunetide). The D-isomer of davunetide is known as AL-408 in the company’s pipeline. This new patent strengthens Allon’s intellectual property estate which includes 15 patent families, 58 issued patents and over 30 pending applications worldwide.
Previous pre-clinical studies have demonstrated that AL-408 shows potent neuroprotective effects in a number of in vitro and in vivo models of neurotoxicity. In an animal model of fetal alcohol syndrome, AL-408 increased survival and improved cognitive performance1. AL-408 has also shown potential neuroprotective activity in a preclinical model of amyotrophic lateral sclerosis (ALS)2.
Dr. Alistair Stewart, Allon’s Vice President of Commercial Research, said this new U.S. patent provides protection for an important early-stage compound within the Company’s product pipeline. “Allon’s technology platform of neuroprotective peptides derived from naturally occurring brain proteins shows broad neuroprotective effects in a variety of diseases and conditions”, explains Stewart. “AL-408 has shown some interesting early-stage research results in areas outside of neurodegenerative diseases, further diversifying and adding value to our product pipeline.”
Allon’s patent portfolio also includes issued patents and pending patent applications that provide protection around davunetide and its technology platform for treatment of neurodegenerative diseases, including progressive supranuclear palsy (PSP), Alzheimer’s disease, and Parkinson’s disease.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
